A new Genomic Medicine Service is in the process of being established to provide a more consistent and equitable genetic testing service to people living throughout England. Its Board brings together senior decision makers across the sector, including key civil servants, delivery partners, patient advocates and representatives from research organisations and industry.
The purpose of the Board is to oversee the implementation of the Chief Medical Officer’s 2016 annual report, Generation Genome and the genomic elements of the Life Sciences Industrial Sector Deal.
Its goal is to make sure that the UK remains the world’s leading centre for genomic medicine and research, and to use this position to deliver quantifiable benefits for NHS patients and the life sciences sector.
For more information click here.